IPX054 200 mg

DRUG3 trials

Sponsors

Impax Laboratories, LLC

Conditions

Idiopathic Parkinson's DiseaseParkinson's Disease

Phase 1

Pharmacokinetics and Pharmacodynamics of IPX054 in Subjects With Parkinson's Disease

CompletedNCT00239564

Impax Laboratories, LLCIdiopathic Parkinson's Disease

Start: 2005-10-31End: 2007-12-31Updated: 2019-10-29

Phase 2

Comparison of IPX054 and Immediate-Release Carbidopa-Levodopa in Patients With Parkinson's Disease

CompletedNCT00253084

Impax Laboratories, LLCParkinson's Disease

Start: 2005-11-30End: 2007-12-31Updated: 2019-10-29

Comparison of IPX054, IR Carbidopa-Levodopa, and CR Carbidopa-Levodopa in Subjects With Parkinson's Disease

CompletedNCT00279825

Impax Laboratories, LLCIdiopathic Parkinson's Disease

Start: 2006-01-31End: 2007-12-31Updated: 2019-10-29